Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESSO 2024 | AI in surgery: enhancing safety, precision, and decision-making through algorithm-guided techniques

Pompiliu Piso • 3 Oct 2024
ESSO 2024
General

Pompiliu Piso, MD, Krankenhaus Barmherzige Brüder Regensburg, Regensburg, Germany, discusses the growing role of artificial intelligence in surgery, emphasizing its potential to enhance patient safety and outcomes through algorithms that suggest optimal dissection lines and improve decision-making. He highlights the challenges in implementing AI, particularly the need for specialists to film procedures for annotation and algorithm development. This interview took place at the ESSO 43 congress in Antwerp, Belgium.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Pompiliu Piso

Debating HIPEC: evaluating effectiveness, refining delivery & the need for Phase III clinical trials
1:18
Debating HIPEC: evaluating effectiveness, refining delivery & the need for Phase III clinical trials
Pompiliu Piso • 3 Oct 2024
Celebrating ESSO's growth, global partnerships, and inspiration from leaders in surgical oncology
1:12
Celebrating ESSO's growth, global partnerships, and inspiration from leaders in surgical oncology
Pompiliu Piso • 3 Oct 2024
The expanding role of robotic surgery in oncology
1:22
The expanding role of robotic surgery in oncology
Pompiliu Piso • 3 Oct 2024
Growing role of AI in robotic surgery to enhance safety and outcomes in oncological procedures
0:49
Growing role of AI in robotic surgery to enhance safety and outcomes in oncological procedures
Pompiliu Piso • 3 Nov 2024

Related Videos

AI governance and validation in robotic cancer surgery
1:12
AI governance and validation in robotic cancer surgery
Marie Hanaoka • 1 Jul 2026
Does toxicity differ between patients treated with SABR for one versus five lesions?
0:39
Does toxicity differ between patients treated with SABR for one versus five lesions?
Robert Olson • 16 May 2026
5-year toxicity following SABR: insights from the SABR-5 trial
0:42
5-year toxicity following SABR: insights from the SABR-5 trial
Robert Olson • 16 May 2026
How should results from the SABR-5 trial guide future SABR studies?
1:05
How should results from the SABR-5 trial guide future SABR studies?
Robert Olson • 16 May 2026
The content of VJOncology is intended for healthcare professionals